Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol evaluates Vanlev

Executive Summary

Bristol-Myers Squibb is reviewing "all relevant options" regarding the future of antihypertensive Vanlev (omapatrilat) following "disappointing news" from FDA's Cardiovascular & Renal Drugs Advisory Committee, CEO Peter Dolan says July 23. The committee said the drug would need a trial in highly refractory patients and a risk management program to support approval (1"The Pink Sheet" July 22, p. 20). "We are currently reviewing the committee discussions, following up with FDA to better understand the agency's point of view and evaluating all relevant options"...
Advertisement

Related Content

Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Bristol Vanlev Trial In Refractory Patients Could Support Approval, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS040212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel